INTRODUCTION
Statins function as competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme for cholesterol synthesis. Data from clinical trials have demonstrated that statin treatment appears to be the most effective and well-tolerated means of lowering cholesterol levels, [1] [2] [3] but it is also clear that large interindividual variations in plasma cholesterol response are common and explained, in part, by genetic factors that affect drug pharmacodynamics and/or pharmacokinetics. In recent years, one of the focus of genetic investigation in cardiology has been to identify the genetic factors associated with variable response to statin treatment. 4, 5 The sterol regulatory element-binding factor (SREBF)-SREBF cleavage-activating protein (SCAP) pathway controls the cellular cholesterol homeostasis. SREBFs are a small family of basic helix-loop-helix-leucine zipper transcription factors. SREBFs proteins share a similar tripartite structure, consisting of an NH 2 -terminal transcription factor domain, a middle hydrophobic region and a COOH-terminal regulatory domain. Newly synthesized SREBFs are embedded both in membranes of the endoplasmatic reticulum (ER) and in the membranes of the nuclear envelope. In this membrane-bound form, SREBF is inactive because its transcription factor domain has no access to the nucleus. 6 SCAP is the key to the activation of SREBFs, fulfilling two functions: it acts as a sterol sensor and escorts SREBFs from the ER to the Golgi, where a two-step proteolytical process releases the transcriptionally active domain from the membranes to enter the nucleus and activates transcription of more than 30 genes encoding proteins that mediate the uptake and synthesis of cholesterol, unsaturated fatty acids and triglycerides (TGs) biosynthesis. [7] [8] [9] [10] Three SREBFs isoforms have been identified and characterized. SREBF-1a and -1c are derived from a single gene located on chromosome 17p11.2 through the use of alternative forms of exon 1. SREBF-2 is derived from a second gene located on chromosome 22q13. 10 The SCAP gene has 23 exons and was assigned to chromosome 3p21.3.
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Given the central role of the SREBF-SCAP pathway in the regulation of lipid metabolism, the objective of this investigation was to evaluate the effect of single-nucleotide polymorphisms (SNPs) in genes encoding SREBF-1a, SREBF-2 and SCAP on the hypolipidemic response to simvastatin treatment.
RESULTS

Characteristics of the Population Study
Demographic, key clinical characteristics and baseline lipid and lipoprotein levels are shown in Table 1 . The subjects were aged between 25 and 82 years (59.2710.7 years) and 25.3% were men. Treatment with 20 mg/day of simvastatin significantly reduced the plasma levels of total cholesterol (TC) (À27.8%, Po0.0001) and low-density lipoprotein cholesterol (LDL-C) (À39.6%, Po0.0001). TG levels were reduced modestly (À10.8%, P ¼ 0.08), while the increase in high-density lipoprotein cholesterol (HDL-C) did not reach statistical significance ( þ 0.7%, P ¼ 0.82). The SREBF-1a -36G, SREBF-2 1784A and SCAP 2386G were present in 49.6%, 27% and 48.4%, respectively, of the chromosomes.
Prediction of Lipid and Lipoprotein Levels Response to Simvastatin SCAP, SREBF-1a and SREBF-2 genotypes were not associated with baseline lipoprotein levels (Table 2) , Age, sex, Body mass index (BMI), concomitant therapies and other key clinical characteristics did not differ by genotype, as well as between responders and nonresponders, but the prevalence of coronary heart disease (CHD) was somewhat higher in nonresponders (15.2%) than in responders group (3.8%, P ¼ 0.05). The SREBF-1a and SREBF-2 gene polymorphisms were also not associated with changes in lipid and lipoproteins levels after treatment (Table 2) .
A significant interaction between the SCAP 2386A4G genotype and statin treatment was observed. As shown in Table 2 , the mean percentage decrease in plasma TC was of the same magnitude in subject carriers of 2386G allele (À29.779.9 and À29.6714.5% for GG and AG genotypes, respectively) and greater than the observed for subjects homozygous for 2386A allele (À22.1713.8%, P ¼ 0.007). A similar trend was observed for plasma LDL-C (À39.7717.3 vs À33.5716.9%, P ¼ 0.088). For these respective genotypes, a significant association with TG levels response was also found: 2386G carriers had TG levels lowered, on average, by 7.9%, while 2386A homozygous had an increase of 8.7% (P ¼ 0.016).
When the mean reduction of TC (À27.8%) was used arbitrarily to divide the subjects into two groups, 61.3% of 2386G carriers had a greater reduction than the mean change of TC, whereas only 29.2% of the homozygous for 2386A allele had lowered their TC above the average value (P ¼ 0.009, Figure 1 ). These results were similar for LDL-C levels, but did not reach statistical significance (P ¼ 0.112, data not shown).
In an attempt to identify important variables associated to the interindividual variability in TC response, multiple regression analysis using TC response as the dependent variable, and age, age 2 , basal TC, diabetes, CAD, hypertension and SCAP genotypes (AA vs AG þ GG) as independent variables was carried out. The model explained 43% of interindividual variation in TC response to simvastatin treatment and SCAP genotypes accounted for 3.1% (P ¼ 0.03, Table 3 ). 11, 12 and is essential for the interaction of SCAP with the carboxy-terminal region of SREBFs and Site-1 protease. 12 Therefore, a substitution in this domain might result in a functional alteration of the SCAP-SREBF interaction.
Few pharmacogenetic investigations with SCAP-SREBF pathway and statin therapy have been reported previously. 13, 14 In one study, Salek et al 13 reported the effect of SCAP and SREBF-1a polymorphisms on hypolipidemic response to fluvastatin treatment. In that investigation, they found a significant genotype-treatment interaction between SREBF-1a polymorphism and changes in apolipoprotein (apo) A-I, apo C-III and HDL-C levels, but did not find any association with SCAP genotypes. Fan et al 14 studied the 
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M Fiegenbaum et al response to pravastatin in 51 men and did not find an influence of SCAP genotypes also. Although the data presented here appear to be inconsistent with these previous investigations, some variables may explain these apparent discrepancies. First, despite a similar mechanism of action for all statins, metabolism and drug interactions could vary considerably among them. Simvastatin is mainly metabolized by CYP3A4, while more than 90% of fluvastatin undergoes CYP2C9 biotransformation and pravastatin is eliminated mainly unchanged. [15] [16] [17] Therefore, differences in genetic variations in drug-metabolizing enzymes and even in other genes associated with lipid metabolism may be important to explain these differences. Second, possible gender differences in response to these medications may occur; in both previous investigations, samples consisted mainly of males, while in our study only 25.3% were men.
There were some limitations to our study. It might have been exposed to factors such as population stratification, but previous investigations have shown an absence of structure in this southern Brazilian population. 18, 19 Moreover, despite the small sample size, our investigation has statistical power (77.1%) to detect a pharmacogenetic influence of differential responses to simvastatin treatment as a function of SCAP genotype, emphasizing the relevance of this high-frequency SNP of the SCAP gene.
In conclusion, the data presented indicate that SCAP 2386A4G genetic variation has a small but significant impact on the lowering of TC and TG levels in response to simvastatin therapy. Despite the primary phenotypic response to statins being LDL-cholesterol reduction, in the present study, no significant association between changes in plasma LDL-C in response to simvastatin and genotypes were found. However, the observed associations between SCAP genotypes and plasma TC and TG levels are not biologically less plausible, since SCAP regulates, via SREBFs, a number of genes involved in intracellular cholesterol homeostasis. [20] [21] [22] Therefore, it seems that the lipid response might be modulated via the regulation of SREBFs-target gene transcription.
MATERIAL AND METHODS
Study Population and Protocol
In all, 146 hypercholesterolemic patients of European descent, as ascertained by skin color and morphological characteristics, were recruited from Porto Alegre, the capital of Brazil's southernmost state. The city was founded in 1752 by 60 white couples from the Azores Islands. At present, the Caucasians from Porto Alegre are still mainly of Portuguese descent, but Italians, Spaniards and Germans have also contributed to its gene pool. 23 On this prospective study, all patients were screened by physical examination, medical history and clinical laboratory evaluation and were invited to participate in this study. The exclusion criteria included: TGs X4.52 mmol/l, unstable/uncontrolled clinically significant disease, uncontrolled hypothyroidism or diabetes, and impaired hepatic or renal function. Patients entering the study were treated with simvastatin (Zocor, Merck Sharp & Dohme) 20 mg/day for over 6 months. Patients remained on other medications throughout the study with no change, including calcium channel blockers, beta-blockers, diuretics and other antihypertensive therapy (Table 1) . Plasma lipid and lipoproteins levels were measured at baseline and throughout the study. The Ethics Committee of the Federal University of Rio Grande do Sul approved the study protocol. All participants of the study gave written informed consent. In total, 99 patients completed the 6-month follow-up and were used for association analysis with efficacy of treatment. In all, 17 subjects presented adverse drug reactions and 30 were excluded due to low compliance with simvastatin treatment.
Biochemical Analysis
Blood samples, at baseline and 6 months after the beginning of the treatment, were collected after 12 h from the fasting subjects. TC, HDL-C, TG, glucose and other relevant biochemical parameters were determined by conventional enzymatic methods. LDL-C was calculated according to Friedewald et al. Genomic DNA was isolated from peripheral blood leukocytes by standard procedures. 25 A 235 bp fragment of the SCAP gene including the 2386A4G polymorphism was amplified by PCR using oligonucleotide primers and restriction mapping with MslI as described by Iwaki et al. 26 The SNPs À36del4G (SREBF-1a) and 1874A4G (SREBF-2) were also genotyped using PCR and restriction mapping with ApaI and MspI as described previously. 27, 28 Statistical Analyses Allele frequencies were estimated by gene counting. The Fisher's exact test was used to assess differences in relative frequencies between groups. Continuous variables were expressed as mean (standard deviation (SD)). TG levels were logtransformed before analysis because of its skewed distribution, but nontransformed values are presented in tables. To determine the genotype association with response to simvastatin treatment, the mean changes in plasma lipid levels among genotypes were compared by a General Linear Model procedure using the type III sums of squares statistics. This sum of squares applies to unbalanced study designs and quantifies the effect of an independent variable after adjustment for all other variables included in the model. Age, gender, smoking status, hypertension, prior cardiovascular disease, diabetes and baseline lipid levels were included in each model as covariates. Multiple regression analysis was performed to determine the percentage of variation explained by each of these variables. Statistical analyses were carried out using the SPSS software package. The significance level was set at Po0.05. The PS Power and Sample Size Calculations Version 2.1.30 was used to calculate the statistical power of the samples. 29 
